Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 3/20 | 0.45 |
| ▸ | KDM4A | O75164 | 3/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.45 |
| ▸ | KDM3B | Q7LBC6 | 3/20 | 0.45 |
| ▸ | HIF1AN | Q9NWT6 | 3/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12144898 | 0.87 | CDC7 (0.50) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL7589855 | 0.86 | LMNA (0.53) | LMNAHTTDAOKDM6BKDM4A | |
| SCHEMBL942486 | 0.84 | NPC1 (0.45) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL12144894 | 0.83 | DAO (0.45) | RAB9ANPC1SMN1; SMN2LMNADAO | |
| SCHEMBL12144892 | 0.81 | DAO (0.39) | RAB9ANPC1SMN1; SMN2DAOALDH1A1 | |
| SCHEMBL7876115 | 0.76 | SMN1; SMN2 (0.50) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL13939871 | 0.73 | DAO (0.45) | RAB9ANPC1SMN1; SMN2HTTDAO | |
| SCHEMBL4158770 | 0.71 | MEN1 (0.51) | RAB9ANPC1SMN1; SMN2LMNAHTT | |
| SCHEMBL7618263 | 0.70 | TAAR1 (0.58) | SMN1; SMN2LMNAHTTDAOKDM4A | |
| SCHEMBL13939842 | 0.70 | NPC1 (0.54) | RAB9ANPC1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966164-B1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067420-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-8012984-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012984-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012984-B2 | Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-06 | — | — | US | disclosed |
| EP-2173725-A2 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | Bristol-Myers Squibb Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009009501-A2 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-08 | — | — | US | disclosed |
| WO-2007071646-A1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | MCHR1, MCHR2, MC1R | RAB9A 1051/4885NPC1 485/4885SMN1; SMN2 695/4885 |
| US-20110144060-A1 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MC1R, MCHR2 | RAB9A 979/4885NPC1 991/4885SMN1; SMN2 2327/4885 |
| US-20110003759-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | RAB9A 650/4885NPC1 686/4885SMN1; SMN2 1839/4885 |
| US-20090011994-A1 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS | MCHR1, MCHR2, MC1R | RAB9A 650/4885NPC1 686/4885SMN1; SMN2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.